Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis
Ribeiro, Ana Luisa de Jesus Lopes Degiacomi, Giulia Ewann, Fanny Buroni, Silvia Incandela, Maria Loreto Chiarelli, Laurent R. Mori, Giorgia Kim, Jaeseung Contreras-Dominguez, Monica Park, Young-Sam Han, Sung-Jun Brodin, Priscille Valentini, Giovanna Rizzi, Menico Riccardi, Giovanna Pasca, Maria Rosalia
PloS one, 2011
Giovanna RICCARDI
RICCARDI Giovanna
ORCID: 0000-0003-3295-0070
Mycobacterium tuberculosis: Drug resistance and future perspectives 10.2217/fmb.09.20
Sequence of the Bacillus stearothermophilus gene encoding aspartokinase II 10.1016/0378-1119(95)00834-9
Antituberculars which target decaprenylphosphoryl-β-Dribofuranose 2′-oxidase DprE1: State of art 10.1007/s00253-012-4013-4
Gene arrangement and organization in a ~ 76 kb fragment: Encompassing the oriC region of the chromosome of Mycobacterium leprae 10.1099/13500872-142-11-3147
Organization of the origins of replication of the chromosomes of Mycobacterium smegmatis, Mycobacterium leprae and Mycobacterium tuberculosis and isolation of a functional origin from M. smegmatis 10.1111/j.1365-2958.1996.tb02617.x
Detection and characterization of naturally occurring plasmids in Bacillus licheniformis 10.1111/j.1574-6968.1991.tb04781.x
Molecular mechanisms of chlorhexidine tolerance in Burkholderia cenocepacia biofilms 10.1128/AAC.01571-10
Differential roles of rnd efflux pumps in antimicrobial drug resistance of sessile and planktonic burkholderia cenocepacia cells 10.1128/AAC.03800-14
Erratum: Antituberculars which target decaprenylphosphoryl-β-D- ribofuranose 2'-oxidase DprE1: State of art (Applied Microbiology and Biotechnology (2012) 94 (907-916) DOI: 10.1007/s00253-012-4013-4) 10.1007/s00253-012-4217-7
Antibiotic resistance of benthic bacteria in fish-farm and control sediments of the Western Mediterranean 10.1016/S0044-8486(03)00016-4
Amino acid biosynthesis and its regulation in cyanobacteria 10.1016/0168-9452(89)90018-6
Characterization of Gram-positive broad host-range plasmids carrying a thermophilic replicon 10.1016/0923-2508(91)90108-M
4-Aminoquinolone piperidine amides: Noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity 10.1021/jm5005978
Evaluation of fluoroquinolone resistance mechanisms in Pseudomonas aeruginosa multidrug resistance clinical isolates 10.1089/mdr.2011.0019
Benzothiazinones Kill Mycobacterium tuberculosis by blocking Arabinan synthesis 10.1126/science.1171583
Assessment of three Resistance-Nodulation-Cell Division drug efflux transporters of Burkholderia cenocepacia in intrinsic antibiotic resistance 10.1186/1471-2180-9-200
Erratum: Global analysis of the Mycobacterium tuberculosis zur (FurB) regulon (Journal of Bacteriology (2007) 189, 3, (730-740)) 10.1128/JB.00593-07
Molecular characterization of the genes encoding acetohydroxy acid synthase in the cyanobacterium Spirulina platensis 10.1099/00221287-138-7-1399
Efflux pump genes of the resistance-nodulation-division family in Burkholderia cenocepacia genome 10.1186/1471-2180-6-66
Role of mycobacterial efflux transporters in drug resistance: An unresolved question 10.1111/j.1574-6976.2005.00002.x
Phenotypic and Genotypic Characterisation of Burkholderia cenocepacia J2315 Mutants Affected in Homoserine Lactone and Diffusible Signal Factor-Based Quorum Sensing Systems Suggests Interplay between Both Types of Systems 10.1371/journal.pone.0055112
Molecular approaches to pathogenesis study of Burkholderia cenocepacia, an important cystic fibrosis opportunistic bacterium 10.1007/s00253-011-3616-5
Heterologous expression, purification, and enzymatic activity of Mycobacterium tuberculosis NAD+ synthetase 10.1016/S1046-5928(02)00041-4
Transcriptional analysis of ESAT-6 cluster 3 in Mycobacterium smegmatis 10.1186/1471-2180-9-48
Genomic analysis of zinc homeostasis in Mycobacterium tuberculosis 10.1111/j.1574-6968.2008.01320.x
Mechanism of resistance to an antitubercular 2-thiopyridine derivative that is also active against Burkholderia cenocepacia 10.1128/AAC.02438-13
Determination of a 15437 bp nucleotide sequence around the inhA gene of Mycobacterium avium and similarity analysis of the products of putative ORFs 10.1099/00221287-144-3-807
Biochemical evidence for multiple forms of acetohydroxy acid synthase in Spirulina platensis 10.1007/BF00252216
Investigating the mechanism of action of diketopiperazines inhibitors of the burkholderia cenocepacia quorum sensing synthase CepI: A site-directed mutagenesis study 10.3389/fphar.2018.00836
Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis 10.1126/scitranslmed.3004395
Biochemical characterization of glutamate Racemase - A new candidate drug target against Burkholderia cenocepacia infections 10.1371/journal.pone.0167350
Cloning and sequencing of the ilvBNC gene cluster from Mycobacterium avium 10.1016/0378-1119(96)00275-2
Rv2466c mediates the activation of TP053 to kill replicating and non-replicating Mycobacterium tuberculosis 10.1021/cb500149m
Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5-MmpL5 efflux system 10.1016/j.tube.2008.08.003
Molecular cloning and expression of Spirulina platensis acetohydroxy acid synthase genes in Escherichia coli 10.1007/BF00243456
Development of a repressible mycobacterial promoter system based on two transcriptional repressors 10.1093/nar/gkq235
Characterisation and antimicrobial activity of epibiotic bacteria from Petrosia ficiformis (Porifera, Demospongiae) 10.1016/j.jembe.2004.03.006
Genetic transformation of intact cells of Bacillus subtilis by electroporation 10.1016/0378-1097(90)90182-P
Transcriptional regulation of furA and katG upon oxidative stress in Mycobacterium smegmatis 10.1128/JB.183.23.6801-6806.2001
Mechanism of action of 5-nitrothiophenes against mycobacterium tuberculosis 10.1128/AAC.02693-13
The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis 10.1007/s00253-013-5218-x
Burkholderia cenocepacia infections in cystic fibrosis patients: Drug resistance and therapeutic approaches 10.3389/fmicb.2017.01592
Structural organization of pBC1, a cryptic plasmid from Bacillus coagulans 10.1128/jb.174.2.638-642.1992
Vaccines to Overcome Antibiotic Resistance: The Challenge of Burkholderia cenocepacia 10.1016/j.tim.2019.12.005
Raising awareness of the importance of funding for tuberculosis small-molecule research 10.1016/j.drudis.2016.09.012
Bacterial community structure and activity in fish farm sediments of the Ligurian Sea (Western Mediterranean) 10.1023/A:1021365829687
Biological and structural characterization of the Mycobacterium smegmatis nitroreductase NfnB, and its role in benzothiazinone resistance 10.1111/j.1365-2958.2010.07277.x
The Crystal Structure of Burkholderia cenocepacia DfsA Provides Insights into Substrate Recognition and Quorum Sensing Fatty Acid Biosynthesis 10.1021/acs.biochem.6b00178
The cell division protein FtsZ as a cellular target to hit cystic fibrosis pathogens 10.1016/j.ejmech.2020.112132
A Phenotypic Based Target Screening Approach Delivers New Antitubercular CTP Synthetase Inhibitors 10.1021/acsinfecdis.7b00006
Deciphering the role of rnd efflux transporters in burkholderia cenocepacia 10.1371/journal.pone.0018902
Exploring the HME and HAE1 efflux systems in the genus Burkholderia 10.1186/1471-2148-10-164
Plasmid screening in thermophilic Bacillus: Physical characterization and molecular cloning 10.1007/BF01568897
The Mycobacterium tuberculosis Rv2358-furB operon is induced by zinc 10.1016/j.resmic.2003.11.009
New prodrugs against tuberculosis 10.1016/j.drudis.2016.09.006
Decaprenylphosphoryl-β-D-ribose 2'-epimerase from Mycobacterium tuberculosis is a magic drug target 10.2174/092986710791959693
Molecular cloning and sequencing of the β-isopropylmalate dehydrogenase gene from the cyanobacterium Spirulina platensis 10.1099/00221287-138-3-493
Cloning of the glutamine synthetase gene from spirulina platensis 10.1007/BF02418760
Characterization of a mutant of chlamydomonas reinhardtII resistant to fusidic acid 10.1016/0014-5793(81)81166-0
Discovery of new diketopiperazines inhibiting Burkholderia cenocepacia quorum sensing in vitro and in vivo 10.1038/srep32487
A highly efficient electroporation system for transformation of Bacillus licheniformis 10.1007/BF00152745
Competitive fitness of essential gene knockdowns reveals a broad-spectrum antibacterial inhibitor of the cell division protein FtsZ 10.1128/AAC.01231-18
A census of RND superfamily proteins in the Burkholderia genus 10.2217/fmb.13.50
LfrR is a repressor that regulates expression of the efflux pump LfrA in Mycobacterium smegmatis 10.1128/AAC.00656-06
Global analysis of the Mycobacterium tuberculosis Zur (FurB) regulon 10.1128/JB.01190-06
Mycobacterium tuberculosis phosphoribosylpyrophosphate synthetase: Biochemical features of a crucial enzyme for mycobacterial cell wall biosynthesis 10.1371/journal.pone.0015494
New tuberculosis drugs on the horizon 10.1016/j.mib.2011.07.022
A multitarget approach to drug discovery inhibiting Mycobacterium tuberculosis PyrG and PanK 10.1038/s41598-018-21614-4
Rv2358 and FurB: Two transcriptional regulators from Mycobacterium tuberculosis which respond to zinc 10.1128/JB.187.16.5837-5840.2005
Mycobacterium tuberculosis H37Rv comparative gene-expression analysis in synthetic medium and human macrophage 10.1016/S0378-1119(00)00249-3
In vitro translation of chloroplast mRNAs 10.1016/0304-4211(82)90148-1
High content screening identifies decaprenyl-phosphoribose 2′ epimerase as a target for intracellular antimycobacterial inhibitors 10.1371/journal.ppat.1000645
The redox state regulates the conformation of Rv2466c to activate the antitubercular prodrug TP053 10.1074/jbc.M115.677039
Biofilm-Grown Burkholderia cepacia Complex Cells Survive Antibiotic Treatment by Avoiding Production of Reactive Oxygen Species 10.1371/journal.pone.0058943
Identification and characterization of a new ligand-binding site in FnbB, a fibronectin-binding adhesin from Streptococcus dysgalactiae 10.1016/S1570-9639(03)00020-7
Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis 10.1371/journal.pone.0026675
Erratum: Rv2358 and FurB: Two transcriptional regulators from Mycobacterium tuberculosis which respond to zinc (Journal of Bacteriology (2005) 187, 16 (5837-5840)) 10.1128/JB.00141-07
Glutamine amidotransferase activity of NAD+ synthetase from Mycobacterium tuberculosis depends on an amino-terminal nitrilase domain 10.1016/j.resmic.2004.08.011
Techniques and Applications: The heterologous expression of Mycobacterium tuberculosis genes is an uphill road 10.1016/S0966-842X(03)00180-X
Characterization of mutants of Spirulina platensis resistant to amino acid analogues 10.1111/j.1574-6968.1981.tb07668.x
The TB structural genomics consortium: A resource for Mycobacterium tuberculosis biology 10.1016/S1472-9792(03)00051-9
Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones 10.1128/AAC.01676-09
New shuttle vector for cloning in Bacillus stearothermophilus 10.1016/0923-2508(94)90074-4
Biochemical characterization and cloning of acetohydroxy acid synthase from spirulina platensis 10.1080/11263509009430656
Structural plasticity and distinct drug-binding modes of LfrR, a mycobacterial efflux pump regulator 10.1128/JB.00631-09
Trends in discovery of new drugs for tuberculosis therapy 10.1038/ja.2014.109
DprE1, a new taxonomic marker in mycobacteria 10.1111/1574-6968.12246
Efflux-mediated resistance to a benzothiadiazol derivative effective against Burkholderia cenocepacia 10.3389/fmicb.2015.00815
mmpL7 gene of Mycobacterium tuberculosis is responsible for isoniazid efflux in Mycobacterium smegmatis 10.1128/AAC.49.11.4775-4777.2005
Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis 10.1128/AAC.48.8.3175-3178.2004
Contribution of the multidrug efflux pump LfrA to innate mycobacterial drug resistance 10.1016/S0378-1097(00)00456-0
Thiophenecarboxamide Derivatives Activated by EthA Kill Mycobacterium tuberculosis by Inhibiting the CTP Synthetase PyrG 10.1016/j.chembiol.2015.05.016
Mycobacterium tuberculosis fura autoregulates its own expression 10.1128/JB.185.18.5357-5362.2003
PEGylated mucus-penetrating nanocrystals for lung delivery of a new FtsZ inhibitor against Burkholderia cenocepacia infection 10.1016/j.nano.2019.102113
Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-β-d-ribofuranose 2′-oxidase DprE1 10.1021/ja211042r
New Insights into the Mechanism of Action of the Thienopyrimidine Antitubercular Prodrug TP053 10.1021/acsinfecdis.9b00388
2-carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1 10.1021/cb5007163
The katE gene, which encodes the catalase HPII of Mycobacterium avium 10.1046/j.1365-2958.1996.352876.x
Sequence of the gene encoding an alkaline serine protease of thermophilic Bacillus smithii 10.1016/0378-1119(94)90340-9
Cloning, sequencing and expression of the ilvBNC gene cluster from Streptomyces avermitilis 10.1016/0378-1119(95)00563-4
Silvia Buroni
Buroni Silvia
ORCID: 0000-0002-6979-2275
Email: silvia.buroni@unipv.it
Mycobacterium tuberculosis: Drug resistance and future perspectives 10.2217/fmb.09.20
Exploring the HME and HAE1 efflux systems in the genus Burkholderia 10.1186/1471-2148-10-164
Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis 10.1126/scitranslmed.3004395
Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis 10.1371/journal.pone.0026675
Glutamine amidotransferase activity of NAD+ synthetase from Mycobacterium tuberculosis depends on an amino-terminal nitrilase domain 10.1016/j.resmic.2004.08.011
Molecular mechanisms of chlorhexidine tolerance in Burkholderia cenocepacia biofilms 10.1128/AAC.01571-10
Decaprenylphosphoryl-β-D-ribose 2'-epimerase from Mycobacterium tuberculosis is a magic drug target 10.2174/092986710791959693
MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212 10.1128/AAC.05270-11
Rv2466c mediates the activation of TP053 to kill replicating and non-replicating Mycobacterium tuberculosis 10.1021/cb500149m
Differential roles of rnd efflux pumps in antimicrobial drug resistance of sessile and planktonic burkholderia cenocepacia cells 10.1128/AAC.03800-14
Discovery of new diketopiperazines inhibiting Burkholderia cenocepacia quorum sensing in vitro and in vivo 10.1038/srep32487
A census of RND superfamily proteins in the Burkholderia genus 10.2217/fmb.13.50
Structural plasticity and distinct drug-binding modes of LfrR, a mycobacterial efflux pump regulator 10.1128/JB.00631-09
LfrR is a repressor that regulates expression of the efflux pump LfrA in Mycobacterium smegmatis 10.1128/AAC.00656-06
Evaluation of fluoroquinolone resistance mechanisms in Pseudomonas aeruginosa multidrug resistance clinical isolates 10.1089/mdr.2011.0019
Mycobacterium tuberculosis phosphoribosylpyrophosphate synthetase: Biochemical features of a crucial enzyme for mycobacterial cell wall biosynthesis 10.1371/journal.pone.0015494
Efflux-mediated resistance to a benzothiadiazol derivative effective against Burkholderia cenocepacia 10.3389/fmicb.2015.00815
Benzothiazinones Kill Mycobacterium tuberculosis by blocking Arabinan synthesis 10.1126/science.1171583
Assessment of three Resistance-Nodulation-Cell Division drug efflux transporters of Burkholderia cenocepacia in intrinsic antibiotic resistance 10.1186/1471-2180-9-200
Efflux pump genes of the resistance-nodulation-division family in Burkholderia cenocepacia genome 10.1186/1471-2180-6-66
Phenotypic and Genotypic Characterisation of Burkholderia cenocepacia J2315 Mutants Affected in Homoserine Lactone and Diffusible Signal Factor-Based Quorum Sensing Systems Suggests Interplay between Both Types of Systems 10.1371/journal.pone.0055112
Biological and structural characterization of the Mycobacterium smegmatis nitroreductase NfnB, and its role in benzothiazinone resistance 10.1111/j.1365-2958.2010.07277.x
The Crystal Structure of Burkholderia cenocepacia DfsA Provides Insights into Substrate Recognition and Quorum Sensing Fatty Acid Biosynthesis 10.1021/acs.biochem.6b00178
Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-β-d-ribofuranose 2′-oxidase DprE1 10.1021/ja211042r
Mechanism of resistance to an antitubercular 2-thiopyridine derivative that is also active against Burkholderia cenocepacia 10.1128/AAC.02438-13
Deciphering the role of rnd efflux transporters in burkholderia cenocepacia 10.1371/journal.pone.0018902
Erratum: Antituberculars which target decaprenylphosphoryl-β-D- ribofuranose 2'-oxidase DprE1: State of art (Applied Microbiology and Biotechnology (2012) 94 (907-916) DOI: 10.1007/s00253-012-4013-4) 10.1007/s00253-012-4217-7
Antimicrobial activity of six essential oils against Burkholderia cepacia complex: Insights into mechanism(s) of action 10.2217/fmb-2017-0121
Antituberculars which target decaprenylphosphoryl-β-Dribofuranose 2′-oxidase DprE1: State of art 10.1007/s00253-012-4013-4
Subfunctionalization influences the expansion of bacterial multidrug antibiotic resistance 10.1186/s12864-017-4222-4
Biochemical characterization of glutamate Racemase - A new candidate drug target against Burkholderia cenocepacia infections 10.1371/journal.pone.0167350
Burkholderia cenocepacia infections in cystic fibrosis patients: Drug resistance and therapeutic approaches 10.3389/fmicb.2017.01592
The Effect of 2-Thiocyanatopyridine Derivative 11026103 on Burkholderia Cenocepacia: Resistance Mechanisms and Systemic Impact 10.3390/antibiotics8040159
Various Evolutionary Trajectories Lead to Loss of the Tobramycin-Potentiating Activity of the Quorum-Sensing Inhibitor Baicalin Hydrate in Burkholderia cenocepacia Biofilms 10.1128/AAC.02092-18
Phenylacetyl coenzyme a, not phenylacetic acid, attenuates CepIR-regulated virulence in Burkholderia cenocepacia 10.1128/AEM.01594-19
PEGylated mucus-penetrating nanocrystals for lung delivery of a new FtsZ inhibitor against Burkholderia cenocepacia infection 10.1016/j.nano.2019.102113
Editorial: Evolution of Genetic Mechanisms of Antibiotic Resistance 10.3389/fgene.2019.00983
Investigating the mechanism of action of diketopiperazines inhibitors of the burkholderia cenocepacia quorum sensing synthase CepI: A site-directed mutagenesis study 10.3389/fphar.2018.00836
Quorum sensing as antivirulence target in cystic fibrosis pathogens 10.3390/ijms20081838
The cell division protein FtsZ as a cellular target to hit cystic fibrosis pathogens 10.1016/j.ejmech.2020.112132
Vaccines to Overcome Antibiotic Resistance: The Challenge of Burkholderia cenocepacia 10.1016/j.tim.2019.12.005
Competitive fitness of essential gene knockdowns reveals a broad-spectrum antibacterial inhibitor of the cell division protein FtsZ 10.1128/AAC.01231-18
Molecular Characterization of the Burkholderia cenocepacia dcw Operon and FtsZ Interactors as New Targets for Novel Antimicrobial Design 10.3390/antibiotics9120841
Role of RND Efflux Pumps in Drug Resistance of Cystic Fibrosis Pathogens 10.3390/antibiotics10070863
Antistaphylococcal Activity of the FtsZ Inhibitor C109 10.3390/pathogens10070886
Giulia Degiacomi
Degiacomi Giulia
ORCID: 0000-0002-3626-8311
Mycobacterium abscessus, an emerging and worrisome pathogen among cystic fibrosis patients 10.3390/ijms20235868
Promoter mutagenesis for fine-tuning expression of essential genes in Mycobacterium tuberculosis 10.1111/1751-7915.12875
A multitarget approach to drug discovery inhibiting Mycobacterium tuberculosis PyrG and PanK 10.1038/s41598-018-21614-4
First triclosan-based macrocyclic inhibitors of InhA enzyme 10.1016/j.bioorg.2019.103498
New Insights into the Mechanism of Action of the Thienopyrimidine Antitubercular Prodrug TP053 10.1021/acsinfecdis.9b00388
The antibacterial prodrug activator Rv2466c is a mycothiol-dependent reductase in the oxidative stress response of Mycobacterium tuberculosis 10.1074/jbc.M117.797837
PknG senses amino acid availability to control metabolism and virulence of Mycobacterium tuberculosis 10.1371/journal.ppat.1006399
A Phenotypic Based Target Screening Approach Delivers New Antitubercular CTP Synthetase Inhibitors 10.1021/acsinfecdis.7b00006
Essentiality of mmpL3 and impact of its silencing on Mycobacterium tuberculosis gene expression 10.1038/srep43495
Micrococcin P1 – A bactericidal thiopeptide active against Mycobacterium tuberculosis 10.1016/j.tube.2016.07.011
Thiophenecarboxamide Derivatives Activated by EthA Kill Mycobacterium tuberculosis by Inhibiting the CTP Synthetase PyrG 10.1016/j.chembiol.2015.05.016
Whole cell screen based identification of spiropiperidines with potent antitubercular properties 10.1016/j.bmcl.2015.05.087
The phosphatidyl-myo-inositol mannosyltransferase PimA is essential for Mycobacterium tuberculosis growth in vitro and in vivo 10.1128/JB.01346-13
GarA is an essential regulator of metabolism in mycobacterium tuberculosis 10.1111/mmi.12368
Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis 10.1126/scitranslmed.3004395
Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis 10.1371/journal.pone.0026675
Biological and structural characterization of the Mycobacterium smegmatis nitroreductase NfnB, and its role in benzothiazinone resistance 10.1111/j.1365-2958.2010.07277.x
Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones 10.1128/AAC.01676-09
Rv0579 Is Involved in the Resistance to the TP053 Antitubercular Prodrug 10.3389/fmicb.2020.00292
In vitro Study of Bedaquiline Resistance in Mycobacterium tuberculosis Multi-Drug Resistant Clinical Isolates 10.3389/fmicb.2020.559469
P146 New weapons are necessary to fight Mycobacterium abscessus 10.1016/s1569-1993(20)30481-1
Promiscuous Targets for Antitubercular Drug Discovery: The Paradigm of DprE1 and MmpL3 10.3390/app10020623
Antituberculars which target decaprenylphosphoryl-β-Dribofuranose 2′-oxidase DprE1: State of art 10.1007/s00253-012-4013-4
Erratum to The Phosphatidyl-myo-Inositol Mannosyltransferase PimA Is Essential for Mycobacterium tuberculosis Growth In Vitro and In Vivo [Journal of Bacteriology, 196, 19, (2014) 3441-3451] DOI: 10.1128/JB.02332-14 10.1128/JB.02332-14
Erratum: Antituberculars which target decaprenylphosphoryl-β-D- ribofuranose 2'-oxidase DprE1: State of art (Applied Microbiology and Biotechnology (2012) 94 (907-916) DOI: 10.1007/s00253-012-4013-4) 10.1007/s00253-012-4217-7
Age-related changes in PD-1 expression coincide with increased cytotoxic potential in Vδ2 T cells during infancy 10.1016/j.cellimm.2020.104244
Nitric oxide-releasing compounds for the treatment of lung infections 10.1016/j.drudis.2020.10.027
A Coumarin-Based Analogue of Thiacetazone as Dual Covalent Inhibitor and Potential Fluorescent Label of HadA in Mycobacterium tuberculosis 10.1021/acsinfecdis.0c00325
Design and Synthesis of Pyrano[3,2-b]indolones Showing Antimycobacterial Activity 10.1021/acsinfecdis.0c00622
Priscille Brodin
Brodin Priscille
ORCID: 0000-0003-0991-7344
Email: priscille.brodin@inserm.fr
How can nanoparticles contribute to antituberculosis therapy? 10.1016/j.drudis.2017.01.011
Host-directed therapies offer novel opportunities for the fight against tuberculosis 10.1016/j.drudis.2017.05.005
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone 10.3390/toxins9070227
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone 10.3390/toxins9070227 10.3390/toxins9070227.
Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections 10.2217/nnm-2016-0364
Cyclodextrin-based nanocarriers containing a synergic drug combination: a potential formulation for pulmonary administration of antitubercular drugs 10.1016/j.ijpharm.2017.05.030 10.1016/j.ijpharm.2017.05.030.
Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism 10.1007/s00401-016-1652-z
Host-directed therapies offer novel opportunities for the fight against tuberculosis 10.1016/j.drudis.2017.05.005 10.1016/j.drudis.2017.05.005.
Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria 10.1111/mmi.13535
Impact of pe_ pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis 10.3389/fcimb.2017.00137
LppM impact on the colonization of macrophages by Mycobacterium tuberculosis 10.1111/cmi.12619
Phenotypic assays for Mycobacterium tuberculosis infection 10.1002/cyto.a.23129 10.1002/cyto.a.23129.
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420 10.1126/science.aag1006
A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters 10.1039/c5ob02630j
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro 10.1007/s00705-016-2771-5
Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization 10.1016/j.str.2016.07.009
Mycolactone The amazing analgesic mycobacterial toxin 10.1051/medsci/20163202007
STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection 10.1038/srep29297
2-Carboxyquinoxalines Kill Mycobacterium tuberculosis through Noncovalent Inhibition of DprE1 10.1021/cb5007163
Cytosolic Access of Mycobacterium tuberculosis: Critical Impact of Phagosomal Acidification Control and Demonstration of Occurrence In Vivo 10.1371/journal.ppat.1004650
High content screening in chemical biology: overview and main challenges 10.1051/medsci/20153102016
High-Content Screening Technology Combined with a Human Granuloma Model as a New Approach To Evaluate the Activities of Drugs against Mycobacterium tuberculosis 10.1128/aac.03705-14
Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system 10.1016/j.vaccine.2015.03.083
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro 10.3389/fmicb.2015.00438
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action 10.1128/jvi.01473-15
Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays 10.1007/978-1-4939-2450-9_24
A Microscopic Phenotypic Assay for the Quantification of Intracellular Mycobacteria Adapted for High-throughput/High-content Screening 10.3791/51114
Ligand Efficiency Driven Design of New Inhibitors of Mycobacterium tuberculosis Transcriptional Repressor EthR Using Fragment Growing, Merging, and Linking Approaches 10.1021/jm500422b
Mycobacterial Toxin Induces Analgesia in Buruli Ulcer by Targeting the Angiotensin Pathways 10.1016/j.cell.2014.04.040
Potent antiviral activity of Solanum rantonnetii and the isolated compounds against hepatitis C virus in vitro 10.1016/j.jff.2014.09.022
A novel specific edge effect correction method for RNA interference screenings 10.1093/bioinformatics/btr648
Discovery of Novel N-Phenylphenoxyacetamide Derivatives as EthR Inhibitors and Ethionamide Boosters by Combining High-Throughput Screening and Synthesis 10.1021/jm3003779
Ethionamide Boosters. 2. Combining Bioisosteric Replacement and Structure-Based Drug Design To Solve Pharmacokinetic Issues in a Series of Potent 1,2,4-Oxadiazole EthR Inhibitors 10.1021/jm200825u
The Balance of Apoptotic and Necrotic Cell Death in Mycobacterium tuberculosis Infected Macrophages Is Not Dependent on Bacterial Virulence 10.1371/journal.pone.0047573
Analogous Mechanisms of Resistance to Benzothiazinones and Dinitrobenzamides in Mycobacterium smegmatis 10.1371/journal.pone.0026675
Ethionamide Boosters: Synthesis, Biological Activity, and Structure-Activity Relationships of a Series of 1,2,4-Oxadiazole EthR Inhibitors 10.1021/jm200076a
High-content screening in infectious diseases 10.1016/j.cbpa.2011.05.023
Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ 10.1099/mic.0.038133-0
High Content Phenotypic Cell-Based Visual Screen Identifies Mycobacterium tuberculosis Acyltrehalose-Containing Glycolipids Involved in Phagosome Remodeling 10.1371/journal.ppat.1001100
High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery 10.4155/fmc.10.223
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting 10.1016/j.biomaterials.2009.09.044
Automated High-Throughput siRNA Transfection in Raw 264.7 Macrophages: A Case Study for Optimization Procedure 10.1177/1087057108328762
Benzothiazinones Kill Mycobacterium tuberculosis by Blocking Arabinan Synthesis 10.1126/science.1171583
High Content Screening Identifies Decaprenyl-Phosphoribose 2 ' Epimerase as a Target for Intracellular Antimycobacterial Inhibitors 10.1371/journal.ppat.1000645
Systematic Genetic Nomenclature for Type VII Secretion Systems 10.1371/journal.ppat.1000507
Control of M-tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP 10.1371/journal.ppat.0040033
Aquatic insects and transmission of Mycobacterium ulcerans 10.1051/medsci/20072367572
ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity 10.1128/jb.00469-07
Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis 10.1371/journal.ppat.0030062
Protection against mycobacterium ulcerans lesion development by exposure to aquatic insect saliva 10.1371/journal.pmed.0040064
Support vector machines for automatic detection of tuberculosis bacteria in confocal microscopy images 10.1109/isbi.2007.356794
Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues 10.1016/j.bmc.2006.12.009
An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis 10.1128/iai.74.4.2128-2137.2006
Benzofuro 3,2-f 1 benzopyrans: A new class of antitubercular agents 10.1016/j.bmc.2006.03.033
Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence 10.1128/iai.74.1.88-98.2006
High frequency of CD4(+) T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection 10.1128/iai.02086-05
Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence 10.1128/jb.00631-06
Evaluation of vaccines in the EU TB vaccine cluster using a guinea pig aerosol infection model of tuberculosis 10.1016/j.tube.2004.09.009
Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity 10.1074/jbc.M503515200
Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics 10.1099/mic.0.27799-0
Proteomic identification of M. tuberculosis protein kinase substrates: PknB recruits GarA, a FHA domain-containing protein, through activation loop-mediated interactions 10.1016/j.jmb.2005.05.049
Tuberculosis: from genome to vaccine 10.1586/14760584.4.4.541
Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RDI immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6 10.1128/iai.72.4.2170-2176.2004
Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens 10.1086/421468
ESAT-6 proteins: protective antigens and virulence factors? 10.1016/j.tim.2004.09.007
Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex 10.1099/mic.0.26662-0
CD8(+)-T-cell responses of mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family 10.1128/iai.71.12.7173-7177.2003
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis 10.1038/nm859
A new evolutionary scenario for the Mycobacterium tuberculosis complex 10.1073/pnas.052548299
Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant 10.1128/iai.70.10.5568-5578.2002
Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides 10.1021/bi015732y
Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti 10.1046/j.1365-2958.2002.03237.x
6-Oxocytidine containing oligonucleotides inhibit the HIV-1 integrase in vitro 10.1081/ncn-100002322
Determinants of Mg2+-dependent activities of recombinant human immunodeficiency virus type 1 integrase 10.1021/bi000398b
Inhibition of the human immunodeficiency virus type 1 DNA integration by modified oligonucleotides 10.1023/a:1026631910681
Branched oligonucleotide-intercalator conjugate forming a parallel stranded structure inhibits HIV-1 integrase 10.1016/s0014-5793(99)01350-2
Inhibition of HIV-1 integration by mono- & bi-functionalized triple helix forming oligonucleotides 10.1080/07328319908044831
Optimization of alternate-strand triple helix formation at the 5 '-TpA-3 ' and 5 '-ApT-3 ' junctions 10.1093/nar/27.15.3029
A truncated HIV-1 Tat protein basic domain rapidly translocates through the plasma membrane and accumulates in the cell nucleus 10.1074/jbc.272.25.16010
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids 10.1073/pnas.1707840114
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton 10.15252/embr.201744371
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton 10.15252/embr.201744371 10.15252/embr.201744371.
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles 10.1038/s41598-017-05453-3
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis 10.1038/s41598-017-11843-4 10.1038/s41598-017-11843-4.
Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays 10.1021/acschembio.7b00091
Host-pathogen systems for early drug discovery against tuberculosis 10.1016/j.mib.2017.11.017 10.1016/j.mib.2017.11.017.
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages 10.1016/j.chom.2017.07.020 10.1016/j.chom.2017.07.020. Epub 2017 Aug 31.
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling 10.1016/j.celrep.2017.08.101 10.1016/j.celrep.2017.08.101.
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids 10.1073/pnas.1707840114 10.1073/pnas.1707840114.
Identification of Piperazinylbenzenesulfonamides as New Inhibitors of Claudin-1 Trafficking and Hepatitis C Virus Entry 10.1128/jvi.01982-17
Multiplexed Quantitation of Intraphagocyte Mycobacterium tuberculosis Secreted Protein Effectors 10.1016/j.celrep.2018.03.125
Oxadiazolone derivatives, new promising multi-target inhibitors against M. tuberculosis 10.1016/j.bioorg.2018.08.025
Proteomics of Mycobacterium infection: Moving towards a Better Understanding of Pathogen-Driven immunomodulation 10.3389/fimmu.2018.00086
Synergy between circular bacteriocin AS-48 and ethambutol against Mycobacterium tuberculosis 10.1128/aac.00359-18
The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase 10.1016/j.tube.2018.08.004
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis 10.1038/s41598-017-11843-4
Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs 10.1016/j.ijpharm.2017.05.030
Host-pathogen systems for early drug discovery against tuberculosis 10.1016/j.mib.2017.11.017
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages 10.1016/j.chom.2017.07.020
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling 10.1016/j.celrep.2017.08.101
Phenotypic assays for Mycobacterium tuberculosis infection 10.1002/cyto.a.23129
A fast, fully automated cell segmentation algorithm for high-throughput and high-content screening 10.1002/cyto.a.20627
Compartmentalized Encapsulation of Two Antibiotics in Porous Nanoparticles: an Efficient Strategy to Treat Intracellular Infections 10.1002/ppsc.201800360
Spatiotemporal Changes of the Phagosomal Proteome in Dendritic Cells in Response to LPS Stimulation 10.1074/mcp.RA119.001316
Mycolactone as Analgesic: Subcutaneous Bioavailability Parameters 10.3389/fphar.2019.00378
Intrinsic Antibacterial Activity of Nanoparticles Made of β-Cyclodextrins Potentiates Their Effect as Drug Nanocarriers against Tuberculosis 10.1021/acsnano.8b07902
Mitochondrial Dynamics and Activity in Legionella-Infected Cells 10.1007/978-1-4939-9048-1_13
Heparin-Binding Hemagglutinin Adhesin (HBHA) Is Involved in Intracytosolic Lipid Inclusions Formation in Mycobacteria 10.3389/fmicb.2018.02258
Dehydrojuncusol, a Natural Phenanthrene Compound Extracted from Juncus maritimus, Is a New Inhibitor of Hepatitis C Virus RNA Replication 10.1128/jvi.02009-18
A novel codrug made of the combination of ethionamide and its potentiating booster: synthesis, self-assembly into nanoparticles and antimycobacterial evaluation 10.1039/C9OB00680J
Could Mycolactone Inspire New Potent Analgesics? Perspectives and Pitfalls 10.3390/toxins11090516
Paradoxical Roles of the MAL/Tirap Adaptor in Pathologies. 10.3389/fimmu.2020.569127
Fragment-Based Optimized EthR Inhibitors with in Vivo Ethionamide Boosting Activity. 10.1021/acsinfecdis.9b00277
Intracellular and in vivo evaluation of imidazo[2,1-b]thiazole-5-carboxamide anti-tuberculosis compounds. 10.1371/journal.pone.0227224
Preclinical assessment of a new live attenuated Mycobacterium tuberculosis Beijing-based vaccine for tuberculosis. 10.1016/j.vaccine.2019.11.085
IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection 10.1101/761551
Worms' Antimicrobial Peptides. 10.3390/md17090512
Theaflavins, polyphenols of black tea, inhibit entry of hepatitis C virus in cell culture. 10.1371/journal.pone.0198226
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro. 10.3389/fmicb.2015.00488
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. 10.1038/nm.3262
Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis. 10.1021/jm300377g
Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease. 10.1186/1753-6561-5-s1-p38
Automated HTS/HCS for antivirals using visual HIV full replication assays. 10.1186/1742-4690-6-s2-p82
Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system. 10.4049/jimmunol.174.6.3570
Cell microbiology interview 10.1111/cmi.13288
Pathogenomic analyses of Mycobacterium microti, an ESX-1-deleted member of the Mycobacterium tuberculosis complex causing disease in various hosts 10.1099/mgen.0.000505
Nathalie deboosere
deboosere Nathalie
ORCID: 0000-0002-2873-5485
ArfGAP1 restricts Mycobacterium tuberculosis entry by controlling the actin cytoskeleton. 10.15252/embr.201744371
Mycobacterium tuberculosis Controls Phagosomal Acidification by Targeting CISH-Mediated Signaling. 10.1016/j.celrep.2017.08.101
A Bacterial Toxin with Analgesic Properties: Hyperpolarization of DRG Neurons by Mycolactone. 10.3390/toxins9070227
Phenotypic assays for Mycobacterium tuberculosis infection. 10.1002/cyto.a.23129
Fragment-Sized EthR Inhibitors Exhibit Exceptionally Strong Ethionamide Boosting Effect in Whole-Cell Mycobacterium tuberculosis Assays. 10.1021/acschembio.7b00091
STAT3 Represses Nitric Oxide Synthesis in Human Macrophages upon Mycobacterium tuberculosis Infection. 10.1038/srep29297
LppM impact on the colonization of macrophages by Mycobacterium tuberculosis. 10.1111/cmi.12619
A microscopic phenotypic assay for the quantification of intracellular mycobacteria adapted for high-throughput/high-content screening. 10.3791/51114
Adhesion of human pathogenic enteric viruses and surrogate viruses to inert and vegetal food surfaces. 10.1016/j.fm.2012.04.007
Viral elution and concentration method for detection of influenza A viruses in mud by real-time RT-PCR. 10.1016/j.jviromet.2011.10.013
Comparison of chlorine and peroxyacetic-based disinfectant to inactivate Feline calicivirus, Murine norovirus and Hepatitis A virus on lettuce. 10.1016/j.ijfoodmicro.2011.08.011
Direct detection of highly pathogenic avian influenza A/H5N1 virus from mud specimens. 10.1016/j.jviromet.2011.06.002
Development and validation of a concentration method for the detection of influenza a viruses from large volumes of surface water. 10.1128/aem.02484-10
A predictive microbiology approach for thermal inactivation of Hepatitis A virus in acidified berries. 10.1016/j.fm.2010.05.018
Assessment of the removal and inactivation of influenza viruses H5N1 and H1N1 by drinking water treatment. 10.1016/j.watres.2010.01.013
Intra-laboratory validation of a concentration method adapted for the enumeration of infectious F-specific RNA coliphage, enterovirus, and hepatitis A virus from inoculated leaves of salad vegetables. 10.1016/j.ijfoodmicro.2005.11.007
Modelling effect of physical and chemical parameters on heat inactivation kinetics of hepatitis A virus in a fruit model system. 10.1016/j.ijfoodmicro.2003.10.015
Host-pathogen systems for early drug discovery against tuberculosis. 10.1016/j.mib.2017.11.017
Mycobacterium tuberculosis inhibits human innate immune responses via the production of TLR2 antagonist glycolipids. 10.1073/pnas.1707840114
Cyclipostins and Cyclophostin analogs as promising compounds in the fight against tuberculosis. 10.1038/s41598-017-11843-4
Legionella pneumophila Modulates Mitochondrial Dynamics to Trigger Metabolic Repurposing of Infected Macrophages. 10.1016/j.chom.2017.07.020
Combination therapy for tuberculosis treatment: pulmonary administration of ethionamide and booster co-loaded nanoparticles. 10.1038/s41598-017-05453-3
Host-directed therapies offer novel opportunities for the fight against tuberculosis. 10.1016/j.drudis.2017.05.005
Cyclodextrin-based nanocarriers containing a synergic drug combination: A potential formulation for pulmonary administration of antitubercular drugs. 10.1016/j.ijpharm.2017.05.030
Impact of pe_pgrs33 Gene Polymorphisms on Mycobacterium tuberculosis Infection and Pathogenesis. 10.3389/fcimb.2017.00137
Clofazimine encapsulation in nanoporous silica particles for the oral treatment of antibiotic-resistant Mycobacterium tuberculosis infections. 10.2217/nnm-2016-0364
Reversion of antibiotic resistance in Mycobacterium tuberculosis by spiroisoxazoline SMARt-420. 10.1126/science.aag1006
How can nanoparticles contribute to antituberculosis therapy? 10.1016/j.drudis.2017.01.011
Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism. 10.1007/s00401-016-1652-z
Identification of aminopyrimidine-sulfonamides as potent modulators of Wag31-mediated cell elongation in mycobacteria. 10.1111/mmi.13535
Mycobacterium tuberculosis LppM Displays an Original Structure and Domain Composition Linked to a Dual Localization. 10.1016/j.str.2016.07.009
Khaya grandifoliola C.DC: a potential source of active ingredients against hepatitis C virus in vitro. 10.1007/s00705-016-2771-5
[Mycolactone: the amazing analgesic mycobacterial toxin]. 10.1051/medsci/20163202007
A fragment merging approach towards the development of small molecule inhibitors of Mycobacterium tuberculosis EthR for use as ethionamide boosters. 10.1039/c5ob02630j
Polyphenols Inhibit Hepatitis C Virus Entry by a New Mechanism of Action. 10.1128/jvi.01473-15
Plant extracts from Cameroonian medicinal plants strongly inhibit hepatitis C virus infection in vitro. 10.3389/fmicb.2015.00488
Increased protective efficacy of recombinant BCG strains expressing virulence-neutral proteins of the ESX-1 secretion system. 10.1016/j.vaccine.2015.03.083
Cytosolic access of Mycobacterium tuberculosis: critical impact of phagosomal acidification control and demonstration of occurrence in vivo. 10.1371/journal.ppat.1004650
[High content screening in chemical biology: overview and main challenges]. 10.1051/medsci/20153102016
Testing chemical and genetic Modulators in Mycobacterium tuberculosis infected cells using phenotypic assays. 10.1007/978-1-4939-2450-9_24
2-Carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1. 10.1021/cb5007163
High-content screening technology combined with a human granuloma model as a new approach to evaluate the activities of drugs against Mycobacterium tuberculosis. 10.1128/aac.03705-14
Mycobacterial toxin induces analgesia in buruli ulcer by targeting the angiotensin pathways. 10.1016/j.cell.2014.04.040
Ligand efficiency driven design of new inhibitors of Mycobacterium tuberculosis transcriptional repressor EthR using fragment growing, merging, and linking approaches. 10.1021/jm500422b
Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. 10.1038/nm.3262
The balance of apoptotic and necrotic cell death in Mycobacterium tuberculosis infected macrophages is not dependent on bacterial virulence. 10.1371/journal.pone.0047573
Discovery of novel N-phenylphenoxyacetamide derivatives as EthR inhibitors and ethionamide boosters by combining high-throughput screening and synthesis. 10.1021/jm300377g
Ethionamide boosters. 2. Combining bioisosteric replacement and structure-based drug design to solve pharmacokinetic issues in a series of potent 1,2,4-oxadiazole EthR inhibitors. 10.1021/jm200825u
A novel specific edge effect correction method for RNA interference screenings. 10.1093/bioinformatics/btr648
Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis. 10.1371/journal.pone.0026675
High-content screening in infectious diseases. 10.1016/j.cbpa.2011.05.023
Ethionamide boosters: synthesis, biological activity, and structure-activity relationships of a series of 1,2,4-oxadiazole EthR inhibitors. 10.1021/jm200076a
Shortening the drug discovery pipeline: small molecule high content screening for lead discovery in neglected disease. 10.1186/1753-6561-5-s1-p38
High content phenotypic cell-based visual screen identifies Mycobacterium tuberculosis acyltrehalose-containing glycolipids involved in phagosome remodeling. 10.1371/journal.ppat.1001100
High-content imaging of Mycobacterium tuberculosis-infected macrophages: an in vitro model for tuberculosis drug discovery. 10.4155/fmc.10.223
Functional characterization of the Mycobacterium tuberculosis serine/threonine kinase PknJ. 10.1099/mic.0.038133-0
High content screening identifies decaprenyl-phosphoribose 2' epimerase as a target for intracellular antimycobacterial inhibitors. 10.1371/journal.ppat.1000645
Systematic genetic nomenclature for type VII secretion systems. 10.1371/journal.ppat.1000507
Long-circulating DNA lipid nanocapsules as new vector for passive tumor targeting. 10.1016/j.biomaterials.2009.09.044
Automated HTS/HCS for antivirals using visual HIV full replication assays. 10.1186/1742-4690-6-s2-p82
Benzothiazinones kill Mycobacterium tuberculosis by blocking arabinan synthesis. 10.1126/science.1171583
Automated high-throughput siRNA transfection in raw 264.7 macrophages: a case study for optimization procedure. 10.1177/1087057108328762
Control of M. tuberculosis ESAT-6 secretion and specific T cell recognition by PhoP. 10.1371/journal.ppat.0040033
ESAT-6 from Mycobacterium tuberculosis dissociates from its putative chaperone CFP-10 under acidic conditions and exhibits membrane-lysing activity. 10.1128/jb.00469-07
[Aquatic insects and transmission of Mycobacterium ulcerans]. 10.1051/medsci/20072367572
Impact of Mycobacterium ulcerans biofilm on transmissibility to ecological niches and Buruli ulcer pathogenesis. 10.1371/journal.ppat.0030062
Protection against Mycobacterium ulcerans lesion development by exposure to aquatic insect saliva. 10.1371/journal.pmed.0040064
Synthesis and antimycobacterial evaluation of benzofurobenzopyran analogues. 10.1016/j.bmc.2006.12.009
Inactivation of Rv2525c, a substrate of the twin arginine translocation (Tat) system of Mycobacterium tuberculosis, increases beta-lactam susceptibility and virulence. 10.1128/jb.00631-06
High frequency of CD4+ T cells specific for the TB10.4 protein correlates with protection against Mycobacterium tuberculosis infection. 10.1128/iai.02086-05
Benzofuro[3,2-f][1]benzopyrans: a new class of antitubercular agents. 10.1016/j.bmc.2006.03.033
An increase in antimycobacterial Th1-cell responses by prime-boost protocols of immunization does not enhance protection against tuberculosis. 10.1128/iai.74.4.2128-2137.2006
Dissection of ESAT-6 system 1 of Mycobacterium tuberculosis and impact on immunogenicity and virulence. 10.1128/iai.74.1.88-98.2006
Tuberculosis: from genome to vaccine. 10.1586/14760584.4.4.541
Functional analysis of early secreted antigenic target-6, the dominant T-cell antigen of Mycobacterium tuberculosis, reveals key residues involved in secretion, complex formation, virulence, and immunogenicity. 10.1074/jbc.m503515200
Immunogenic membrane-associated proteins of Mycobacterium tuberculosis revealed by proteomics. 10.1099/mic.0.27799-0
Influence of ESAT-6 secretion system 1 (RD1) of Mycobacterium tuberculosis on the interaction between mycobacteria and the host immune system. 10.4049/jimmunol.174.6.3570
Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis. 10.1016/j.tube.2004.09.009
ESAT-6 proteins: protective antigens and virulence factors? 10.1016/j.tim.2004.09.007
Enhanced protection against tuberculosis by vaccination with recombinant Mycobacterium microti vaccine that induces T cell immunity against region of difference 1 antigens. 10.1086/421468
Cell envelope protein PPE68 contributes to Mycobacterium tuberculosis RD1 immunogenicity independently of a 10-kilodalton culture filtrate protein and ESAT-6. 10.1128/iai.72.4.2170-2176.2004
Macro-array and bioinformatic analyses reveal mycobacterial 'core' genes, variation in the ESAT-6 gene family and new phylogenetic markers for the Mycobacterium tuberculosis complex. 10.1099/mic.0.26662-0
CD8+-T-cell responses of Mycobacterium-infected mice to a newly identified major histocompatibility complex class I-restricted epitope shared by proteins of the ESAT-6 family. 10.1128/iai.71.12.7173-7177.2003
Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis. 10.1038/nm859
Loss of RD1 contributed to the attenuation of the live tuberculosis vaccines Mycobacterium bovis BCG and Mycobacterium microti. 10.1046/j.1365-2958.2002.03237.x
Bacterial artificial chromosome-based comparative genomic analysis identifies Mycobacterium microti as a natural ESAT-6 deletion mutant. 10.1128/iai.70.10.5568-5578.2002
Disruption of HIV-1 integrase-DNA complexes by short 6-oxocytosine-containing oligonucleotides. 10.1021/bi015732y
IRG1 controls immunometabolic host response and restricts intracellular Mycobacterium tuberculosis infection 10.1101/761551
Large scale screening discovers clofoctol as an inhibitor of SARS-CoV-2 replication that reduces COVID-19-like pathology 10.1101/2021.06.30.450483
Giorgia Mori
Mori Giorgia
ORCID: 0000-0003-3469-5632
Pyridine-3,4-dicarboximide as starting material for the total synthesis of the natural product eupolauramine and its isomer iso-eupolauramine endowed with anti-tubercular activities 10.1016/j.tet.2015.01.034
DprE1, a new taxonomic marker in mycobacteria 10.1111/1574-6968.12246
Design, synthesis and evaluation of new GEQ derivatives as inhibitors of InhA enzyme and Mycobacterium tuberculosis growth 10.1016/j.ejmech.2015.06.035
Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis 10.1371/journal.pone.0026675
Synthesis of 3-heteryl substituted pyrrolidine-2,5-diones via catalytic Michael reaction and evaluation of their inhibitory activity against InhA and Mycobacterium tuberculosis 10.1016/j.ejmech.2013.10.069
New prodrugs against tuberculosis 10.1016/j.drudis.2016.09.006
Evaluation of the inhibitory activity of (aza)isoindolinone-type compounds: toward in vitro InhA action, Mycobacterium tuberculosis growth and mycolic acid biosynthesis 10.1111/cbdd.12804
Thiophenecarboxamide Derivatives Activated by EthA Kill Mycobacterium tuberculosis by Inhibiting the CTP Synthetase PyrG 10.1016/j.chembiol.2015.05.016
Design, Syntheses, and Anti-TB Activity of 1,3-Benzothiazinone Azide and Click Chemistry Products Inspired by BTZ043 10.1021/acsmedchemlett.5b00424
Rv2466c mediates the activation of TP053 to kill replicating and non-replicating Mycobacterium tuberculosis 10.1021/cb500149m
Pyrrolidinone and pyrrolidine derivatives: Evaluation as inhibitors of InhA and Mycobacterium tuberculosis 10.1016/j.ejmech.2016.07.028
Triazolophthalazines: Easily Accessible Compounds with Potent Antitubercular Activity 10.1002/cmdc.201600085
2-carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1 10.1021/cb5007163
New and old hot drug targets in tuberculosis 10.2174/1389557516666160831164925
A Phenotypic Based Target Screening Approach Delivers New Antitubercular CTP Synthetase Inhibitors 10.1021/acsinfecdis.7b00006
Mechanochemical synthesis and biological evaluation of novel isoniazid derivatives with potent antitubercular activity 10.3390/molecules22091457
Evaluation of heteroatom-rich derivatives as antitubercular agents with InhA inhibition properties 10.1007/s00044-017-2064-x
Shifts of Faecal Microbiota during Sporadic Colorectal Carcinogenesis 10.1038/s41598-018-28671-9
Discovery and development of novel salicylate synthase (MbtI) furanic inhibitors as antitubercular agents 10.1016/j.ejmech.2018.06.033
The EU approved antimalarial pyronaridine shows antitubercular activity and synergy with rifampicin, targeting RNA polymerase 10.1016/j.tube.2018.08.004
A multitarget approach to drug discovery inhibiting Mycobacterium tuberculosis PyrG and PanK 10.1038/s41598-018-21614-4
Synthesis, oxidation potential and anti–mycobacterial activity of isoniazid and analogues: insights into the molecular isoniazid activation mechanism 10.1002/slct.201600040
Gut microbiota analysis in postoperative lynch syndrome patients 10.3389/fmicb.2019.01746
Gut Microbial Signatures in Sporadic and Hereditary Colorectal Cancer 10.3390/ijms22031312
2-Aminooxazole as a Novel Privileged Scaffold in Antitubercular Medicinal Chemistry. 10.1021/acsmedchemlett.0c00173
Rv0579 Is Involved in the Resistance to the TP053 Antitubercular Prodrug. 10.3389/fmicb.2020.00292
New Insights into the Mechanism of Action of the Thienopyrimidine Antitubercular Prodrug TP053. 10.1021/acsinfecdis.9b00388
Laurent Roberto Chiarelli
Chiarelli Laurent Roberto
ORCID: 0000-0003-0348-9764
Tackling Critical Catalytic Residues in Helicobacter pylori L-Asparaginase 10.3390/biom5020306
Thiophenecarboxamide Derivatives Activated by EthA Kill Mycobacterium tuberculosis by Inhibiting the CTP Synthetase PyrG 10.1016/j.chembiol.2015.05.016
Engineering of helicobacter pylori lasparaginase: Characterization of two functionally distinct groups of mutants e0117025 10.1371/journal.pone.0117025
2-carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1 10.1021/cb5007163
Rv2466c mediates the activation of TP053 to kill replicating and non-replicating Mycobacterium tuberculosis 10.1021/cb500149m
Mechanism of action of 5-nitrothiophenes against mycobacterium tuberculosis 10.1128/AAC.02693-13
Biochemistry of lipolytic enzymes secreted by Penicillium solitum and Cladosporium cladosporioides 10.1080/09168451.2014.882752
4-Aminoquinolone piperidine amides: Noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity 10.1021/jm5005978
The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis 10.1007/s00253-013-5218-x
Structural and energetic basis of protein kinetic destabilization in human phosphoglycerate kinase 1 deficiency 10.1021/bi301565m
Protein recognition by short peptide reversible inhibitors of the chromatin-modifying LSD1/CoREST lysine demethylase 10.1021/cb4001926
Monitoring of inosine monophosphate dehydrogenase activity and expression during the early period of mycophenolate mofetil therapy in de novo renal transplant patients 10.2133/dmpk.DMPK-12-RG-048
BEL -trefoil: A novel lectin with antineoplastic properties in king bolete (Boletus edulis) mushrooms 10.1093/glycob/cws164
Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis 10.1126/scitranslmed.3004395
Molecular insights on pathogenic effects of mutations causing phosphoglycerate kinase deficiency 10.1371/journal.pone.0032065
Letter to the Editor regarding Shibayama etal.: Biochemical and pathophysiological characterization of Helicobacter pylori asparaginase 10.1111/j.1348-0421.2012.00460.x
A new variant of phosphoglycerate kinase deficiency (p.I371K) with multiple tissue involvement: Molecular and functional characterization 10.1016/j.ymgme.2012.05.015
Structure of a lectin with antitumoral properties in king bolete (Boletus edulis) mushrooms 10.1093/glycob/cwr012
Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis 10.1371/journal.pone.0026675
Mycobacterium tuberculosis phosphoribosylpyrophosphate synthetase: Biochemical features of a crucial enzyme for mycobacterial cell wall biosynthesis 10.1371/journal.pone.0015494
Inosine monophosphate dehydrogenase variability in renal transplant patients on long-term mycophenolate mofetil therapy 10.1111/j.1365-2125.2009.03542.x
Cell-cycle inhibition by Helicobacter pylori L-asparaginase 10.1371/journal.pone.0013892
Biological and structural characterization of the Mycobacterium smegmatis nitroreductase NfnB, and its role in benzothiazinone resistance 10.1111/j.1365-2958.2010.07277.x
Biochemical signatures of doppel protein in human astrocytomas to support prediction in tumor malignancy 10.1155/2010/301067
ThermoFAD, a Thermofluor®-adapted flavin ad hoc detection system for protein folding and ligand binding 10.1111/j.1742-4658.2009.07006.x
Molecular basis of pyrimidine 5′-nucleotidase deficiency caused by 3 newly identified missense mutations (c.187T>C, c.469G>C and c.740T>C) and a tabulation of known mutations 10.1016/j.bcmd.2007.10.005
Helicobacter pylori l-asparaginase: A promising chemotherapeutic agent 10.1016/j.bbrc.2008.10.118
Pyruvate kinase deficiency: The genotype-phenotype association 10.1016/j.blre.2007.01.001
Erythrocyte adenylate kinase deficiency: characterization of recombinant mutant forms and relationship with nonspherocytic hemolytic anemia 10.1016/j.exphem.2007.05.004
Hereditary erythrocyte pyrimidine 5′-nucleotidase deficiency: A biochemical, genetic and clinical overview 10.1080/10245330500276667
Red cell pyruvate kinase deficiency: 17 New mutations of the PK-LR gene 10.1111/j.1365-2141.2005.05520.x
Functional analysis of pyrimidine 5′-nucleotidase mutants causing nonspherocytic hemolytic anemia 10.1182/blood-2004-10-3895
Pyrimidine 5′-nucleotidase activities detected in real samples by means of micellar electrokinetic chromatography 10.1002/elps.200406057
Structure and function of human erythrocyte pyruvate kinase: Molecular basis of nonspherocytic hemolytic anemia 10.1074/jbc.M202107200
Human erythrocyte pyruvate kinase: Characterization of the recombinant enzyme and a mutant form (R510Q) causing nonspherocytic hemolytic anemia 10.1182/blood.V98.10.3113
The allosteric regulation of pyruvate kinase: A site-directed mutagenesis study 10.1074/jbc.M001870200
Micellar electrokinetic chromatography as a complementary method to sodium dodecyl sulfate-polyacrylamide gel electrophoresis for studying limited proteolysis of proteins 10.1002/(SICI)1522-2683(19990801)20:12<2400::AID-ELPS2400>3.0.CO;2-T
The redox state regulates the conformation of Rv2466c to activate the antitubercular prodrug TP053 10.1074/jbc.M115.677039
Design, Syntheses, and Anti-TB Activity of 1,3-Benzothiazinone Azide and Click Chemistry Products Inspired by BTZ043 10.1021/acsmedchemlett.5b00424
Micellar electrokinetic chromatography as a complementary method to sodium dodecyl sulfate-polyacrylamide gel electrophoresis for studying limited proteolysis of proteins 10.1002/(SICI)1522-2683(19990801)20:12<2400::AID-ELPS2400>3.0.CO;2-T
The Crystal Structure of Burkholderia cenocepacia DfsA Provides Insights into Substrate Recognition and Quorum Sensing Fatty Acid Biosynthesis 10.1021/acs.biochem.6b00178
Biochemical Characterization of Glutamate Racemase—A New Candidate Drug Target against Burkholderia cenocepacia Infections 10.1371/journal.pone.0167350
Iron acquisition pathways as targets for antitubercular drugs 10.2174/0929867323666160607223747
New and old hot drug targets in tuberculosis 10.2174/1389557516666160831164925
Discovery of new diketopiperazines inhibiting Burkholderia cenocepacia quorum sensing in vitro and in vivo 10.1038/srep32487
New prodrugs against tuberculosis 10.1016/j.drudis.2016.09.006
A Phenotypic Based Target Screening Approach Delivers New Antitubercular CTP Synthetase Inhibitors 10.1021/acsinfecdis.7b00006
Burkholderia cenocepacia infections in cystic fibrosis patients: Drug resistance and therapeutic approaches 10.3389/fmicb.2017.01592
Mechanochemical Synthesis and Biological Evaluation of Novel Isoniazid Derivatives with Potent Antitubercular Activity 10.3390/molecules22091457
A multitarget approach to drug discovery inhibiting Mycobacterium tuberculosis PyrG and PanK 10.1038/s41598-018-21614-4
Discovery and development of novel salicylate synthase (MbtI) furanic inhibitors as antitubercular agents 10.1016/j.ejmech.2018.06.033
New chromane-based derivatives as inhibitors of mycobacterium tuberculosis salicylate synthase (mbti): Preliminary biological evaluation and molecular modeling studies 10.3390/molecules23071506
Investigating the mechanism of action of diketopiperazines inhibitors of the burkholderia cenocepacia quorum sensing synthase CepI: A site-directed mutagenesis study 10.3389/fphar.2018.00836
Expanding Targets for a Metabolic Therapy of Cancer: L-Asparaginase  10.2174/97816080590891140301
The Role of One- and Two-Dimensional Electrophoretic Techniques in Proteomics of the Lung 10.5772/intechopen.75042
Erratum: Red cell pyruvate kinase deficiency: 17 New mutations of the PK-LR gene (British Journal of Haematology (2005) 129, (839-846)) 10.1111/j.1365-2141.2005.05691.x
Competitive fitness of essential gene knockdowns reveals a broad-spectrum antibacterial inhibitor of the cell division protein FtsZ 10.1128/AAC.01231-18
New insight into structure-activity of furan-based salicylate synthase (MbtI) inhibitors as potential antitubercular agents 10.1080/14756366.2019.1589462
Various Evolutionary Trajectories Lead to Loss of the Tobramycin-Potentiating Activity of the Quorum-Sensing Inhibitor Baicalin Hydrate in Burkholderia cenocepacia Biofilms 10.1128/AAC.02092-18
An overview on the potential antimycobacterial agents targeting serine/threonine protein kinases from Mycobacterium tuberculosis 10.2174/1568026619666190227182701
Quorum sensing as antivirulence target in cystic fibrosis pathogens 10.3390/ijms20081838
Phenylacetyl Coenzyme A, Not Phenylacetic Acid, Attenuates CepIR-Regulated Virulence in Burkholderia cenocepacia 10.1128/AEM.01594-19
PEGylated mucus-penetrating nanocrystals for lung delivery of a new FtsZ inhibitor against Burkholderia cenocepacia infection 10.1016/j.nano.2019.102113
New Insights into the Mechanism of Action of the Thienopyrimidine Antitubercular Prodrug TP053 10.1021/acsinfecdis.9b00388
Mycobacterium abscessus, an emerging and worrisome pathogen among cystic fibrosis patients 10.3390/ijms20235868
Promiscuous Targets for Antitubercular Drug Discovery: The Paradigm of DprE1 and MmpL3 10.3390/app10020623
Multitargeting Compounds: A Promising Strategy to Overcome Multi-Drug Resistant Tuberculosis 10.3390/molecules25051239
The cell division protein FtsZ as a cellular target to hit cystic fibrosis pathogens 10.1016/j.ejmech.2020.112132
Rv0579 Is Involved in the Resistance to the TP053 Antitubercular Prodrug 10.3389/fmicb.2020.00292
Antivirulence compounds: a future direction to overcome antibiotic resistance? 10.2217/fmb-2019-0294
6-Hydroxy-2-methylbenzofuran-4-carboxylic Acid 10.3390/M1143
Chemical, Metabolic, and Cellular Characterization of a FtsZ Inhibitor Effective Against Burkholderia cenocepacia 10.3389/fmicb.2020.00562
Shedding X-ray Light on the Role of Magnesium in the Activity of Mycobacterium tuberculosis Salicylate Synthase (MbtI) for Drug Design 10.1021/acs.jmedchem.0c00373
Editorial on Special Issue “Tuberculosis Drug Discovery and Development 2019” 10.3390/app10176069
Design, synthesis and evaluation of covalent inhibitors of DprE1 as antitubercular agents 10.1016/j.ejmech.2020.112773
Nitric oxide-releasing compounds for the treatment of lung infections 10.1016/j.drudis.2020.10.027
Synthesis, Characterization, and Biological Evaluation of New Derivatives Targeting MbtI as Antitubercular Agents 10.3390/ph14020155
A Coumarin-Based Analogue of Thiacetazone as Dual Covalent Inhibitor and Potential Fluorescent Label of HadA in Mycobacterium tuberculosis 10.1021/acsinfecdis.0c00325
Natural products against key Mycobacterium tuberculosis enzymatic targets: Emerging opportunities for drug discovery 10.1016/j.ejmech.2021.113732
The Antimalarial Mefloquine Shows Activity against Mycobacterium abscessus, Inhibiting Mycolic Acid Metabolism 10.3390/ijms22168533
Maria Rosalia PASCA
PASCA Maria Rosalia
ORCID: 0000-0002-8906-4937
Thiophenecarboxamide Derivatives Activated by EthA Kill Mycobacterium tuberculosis by Inhibiting the CTP Synthetase PyrG 10.1016/j.chembiol.2015.05.016
Design, synthesis and evaluation of new GEQ derivatives as inhibitors of InhA enzyme and Mycobacterium tuberculosis growth 10.1016/j.ejmech.2015.06.035
2-carboxyquinoxalines kill mycobacterium tuberculosis through noncovalent inhibition of DprE1 10.1021/cb5007163
Pyridine-3,4-dicarboximide as starting material for the total synthesis of the natural product eupolauramine and its isomer iso-eupolauramine endowed with anti-tubercular activities 10.1016/j.tet.2015.01.034
Differential roles of rnd efflux pumps in antimicrobial drug resistance of sessile and planktonic burkholderia cenocepacia cells 10.1128/AAC.03800-14
Trends in discovery of new drugs for tuberculosis therapy 10.1038/ja.2014.109
Rv2466c mediates the activation of TP053 to kill replicating and non-replicating Mycobacterium tuberculosis 10.1021/cb500149m
4-Aminoquinolone piperidine amides: Noncovalent inhibitors of DprE1 with long residence time and potent antimycobacterial activity 10.1021/jm5005978
Synthesis of 3-heteryl substituted pyrrolidine-2,5-diones via catalytic Michael reaction and evaluation of their inhibitory activity against InhA and Mycobacterium tuberculosis 10.1016/j.ejmech.2013.10.069
DprE1, a new taxonomic marker in mycobacteria 10.1111/1574-6968.12246
The DprE1 enzyme, one of the most vulnerable targets of Mycobacterium tuberculosis 10.1007/s00253-013-5218-x
Synthesis and evaluation of α-ketotriazoles and α,β- diketotriazoles as inhibitors of Mycobacterium tuberculosis 10.1016/j.ejmech.2013.06.042
A census of RND superfamily proteins in the Burkholderia genus 10.2217/fmb.13.50
Improved BM212 MmpL3 Inhibitor Analogue Shows Efficacy in Acute Murine Model of Tuberculosis Infection 10.1371/journal.pone.0056980
Phenotypic and Genotypic Characterisation of Burkholderia cenocepacia J2315 Mutants Affected in Homoserine Lactone and Diffusible Signal Factor-Based Quorum Sensing Systems Suggests Interplay between Both Types of Systems 10.1371/journal.pone.0055112
Design, chemical synthesis of 3-(9H-fluoren-9-yl)pyrrolidine-2,5-dione derivatives and biological activity against enoyl-ACP reductase (InhA) and Mycobacterium tuberculosis 10.1016/j.ejmech.2013.09.041
Structural basis for benzothiazinone-mediated killing of Mycobacterium tuberculosis 10.1126/scitranslmed.3004395
Chemical synthesis and biological evaluation of triazole derivatives as inhibitors of InhA and antituberculosis agents 10.1016/j.ejmech.2012.03.029
Evaluation of fluoroquinolone resistance mechanisms in Pseudomonas aeruginosa multidrug resistance clinical isolates 10.1089/mdr.2011.0019
Benzothiazinones are suicide inhibitors of mycobacterial decaprenylphosphoryl-β-d-ribofuranose 2′-oxidase DprE1 10.1021/ja211042r
MmpL3 is the cellular target of the antitubercular pyrrole derivative BM212 10.1128/AAC.05270-11
Analogous mechanisms of resistance to benzothiazinones and dinitrobenzamides in Mycobacterium smegmatis 10.1371/journal.pone.0026675
Synthesis and biological activities of triazole derivatives as inhibitors of InhA and antituberculosis agents 10.1016/j.ejmech.2011.09.013
Deciphering the role of rnd efflux transporters in burkholderia cenocepacia 10.1371/journal.pone.0018902
Mycobacterium tuberculosis phosphoribosylpyrophosphate synthetase: Biochemical features of a crucial enzyme for mycobacterial cell wall biosynthesis 10.1371/journal.pone.0015494
Biological and structural characterization of the Mycobacterium smegmatis nitroreductase NfnB, and its role in benzothiazinone resistance 10.1111/j.1365-2958.2010.07277.x
Decaprenylphosphoryl-β-D-ribose 2'-epimerase from Mycobacterium tuberculosis is a magic drug target 10.2174/092986710791959693
Exploring the HME and HAE1 efflux systems in the genus Burkholderia 10.1186/1471-2148-10-164
Clinical isolates of Mycobacterium tuberculosis in four European hospitals are uniformly susceptible to benzothiazinones 10.1128/AAC.01676-09
Assessment of three Resistance-Nodulation-Cell Division drug efflux transporters of Burkholderia cenocepacia in intrinsic antibiotic resistance 10.1186/1471-2180-9-200
Control of MRSA infection and colonisation in an intensive care unit by GeneOhm MRSA assay and culture methods 10.1186/1471-2334-9-137
Mycobacterium tuberculosis: Drug resistance and future perspectives 10.2217/fmb.09.20
Benzothiazinones Kill Mycobacterium tuberculosis by blocking Arabinan synthesis 10.1126/science.1171583
Azole resistance in Mycobacterium tuberculosis is mediated by the MmpS5-MmpL5 efflux system 10.1016/j.tube.2008.08.003
Genomic analysis of zinc homeostasis in Mycobacterium tuberculosis 10.1111/j.1574-6968.2008.01320.x
Global analysis of the Mycobacterium tuberculosis Zur (FurB) regulon 10.1128/JB.01190-06
LfrR is a repressor that regulates expression of the efflux pump LfrA in Mycobacterium smegmatis 10.1128/AAC.00656-06
Efflux pump genes of the resistance-nodulation-division family in Burkholderia cenocepacia genome 10.1186/1471-2180-6-66
mmpL7 gene of Mycobacterium tuberculosis is responsible for isoniazid efflux in Mycobacterium smegmatis 10.1128/AAC.49.11.4775-4777.2005
Glutamine amidotransferase activity of NAD+ synthetase from Mycobacterium tuberculosis depends on an amino-terminal nitrilase domain 10.1016/j.resmic.2004.08.011
Characterization and heterologous expression of the oxalyl coenzyme a decarboxylase gene from Bifidobacterium lactis 10.1128/AEM.70.9.5066-5073.2004
Rv2686c-Rv2687c-Rv2688c, an ABC fluoroquinolone efflux pump in Mycobacterium tuberculosis 10.1128/AAC.48.8.3175-3178.2004
The Redox State Regulates the Conformation of Rv2466c to Activate the Antitubercular Prodrug TP053 10.1074/jbc.M115.677039
New Potential Drugs Targets For Burkholderia: Insights From In Silico Analyses 10.1016/j.jbiotec.2010.09.650
Triazolophthalazines: Easily Accessible Compounds with Potent Antitubercular Activity 10.1002/cmdc.201600085
New prodrugs against tuberculosis 10.1016/j.drudis.2016.09.006
Pyrrolidinone and pyrrolidine derivatives: Evaluation as inhibitors of InhA and Mycobacterium tuberculosis. 10.1016/j.ejmech.2016.07.028
Evaluation of the inhibitory activity of (aza)isoindolinone-type compounds: toward in vitro InhA action, Mycobacterium tuberculosis growth and mycolic acid biosynthesis. 10.1111/cbdd.12804
Mechanochemical Synthesis and Biological Evaluation of Novel Isoniazid Derivatives with Potent Antitubercular Activity 10.3390/molecules22091457
Erratum: Antituberculars which target decaprenylphosphoryl-β-D- ribofuranose 2'-oxidase DprE1: State of art (Applied Microbiology and Biotechnology (2012) 94 (907-916) DOI: 10.1007/s00253-012-4013-4) 10.1007/s00253-012-4217-7
Antituberculars which target decaprenylphosphoryl-β-Dribofuranose 2′-oxidase DprE1: State of art 10.1007/s00253-012-4013-4
Shifts of Faecal Microbiota during Sporadic Colorectal Carcinogenesis 10.1038/s41598-018-28671-9
Iron acquisition pathways as targets for antitubercular drugs 10.2174/0929867323666160607223747
New and old hot drug targets in tuberculosis 10.2174/1389557516666160831164925
A Phenotypic Based Target Screening Approach Delivers New Antitubercular CTP Synthetase Inhibitors 10.1021/acsinfecdis.7b00006
A multitarget approach to drug discovery inhibiting Mycobacterium tuberculosis PyrG and PanK 10.1038/s41598-018-21614-4
Promiscuous Targets for Antitubercular Drug Discovery: The Paradigm of DprE1 and MmpL3 10.3390/app10020623
2-Aminooxazole as a Novel Privileged Scaffold in Antitubercular Medicinal Chemistry 10.1021/acsmedchemlett.0c00173
In vitro Study of Bedaquiline Resistance in Mycobacterium tuberculosis Multi-Drug Resistant Clinical Isolates. 10.3389/fmicb.2020.559469
Nitric oxide-releasing compounds for the treatment of lung infections 10.1016/j.drudis.2020.10.027
Gut Microbial Signatures in Sporadic and Hereditary Colorectal Cancer 10.3390/ijms22031312
The Antimalarial Mefloquine Shows Activity against Mycobacterium abscessus, Inhibiting Mycolic Acid Metabolism 10.3390/ijms22168533